Onvansertib
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.
| Catalog Number | T6247 |
| Alternative Name(s) | NMS-P937 , NMS-1286937 |
| Research Area | Apoptosis|||Cell Cycle/Checkpoint |
| Molecular Formula | C24H27F3N8O3 |
| CAS# | 1034616-18-6 |
| Purity | 97.01% |
| SMILES | CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1 |
| Size | 25 mg |
| Supplier Page | https://www.targetmol.com/compound/Onvansertib |
| Additional Information | https://www.targetmol.com/datasheet/T6247 |